Liquid Biopsy Development
Liquid Biopsy Development - Related Videos
05:26
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
0 Views •
Cited by 3 •
2022
The liquid biopsy has revolutionized our approach to oncology translational studies, with sample collection, quality, and storage being crucial steps for its successful clinical application. Here we describe a standardized and validated protocol for downstream circulating-free DNA applications that can be applied in most translational research laboratories.
06:04
Aqueous Humor as a Liquid Biopsy for Retinoblastoma: Clear Corneal Paracentesis and Genomic Analysis
0 Views •
Cited by 36 •
2021
The aqueous humor is a high-yield liquid biopsy for retinoblastoma, intraocular cancer that cannot be biopsied in vivo due to the risk of extraocular spread. Herein, a method for safely extracting aqueous humor via clear corneal paracentesis and steps for genomic analysis to identify prognostic biomarkers are presented.
08:49
Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
0 Views •
Cited by 59 •
2016
This protocol describes the feasibility to perform miRNA profiling in exosomes, released in plasma of NSCLC patients, through a commercial exosome isolation kit with Proteinase K and RNAse treatments, in order to avoid circulating miRNAs contamination and evaluate their biomarker features in NSCLC.
14:54
Biobanking of Human Aqueous and Vitreous Liquid Biopsies for Molecular Analyses
0 Views •
Cited by 7 •
2023
This protocol presents an integrated biorepository platform for the standardized collection, annotation, and biobanking of high-quality human aqueous humor and vitreous liquid biopsies for molecular downstream analyses, including proteomics, metabolomics, and glycomics.
09:01
A Technique for Subcutaneous Abdominal Adipose Tissue Biopsy via a Non-diathermy Method
0 Views •
Cited by 7 •
2017
We standardized an abdominal adipose tissue biopsy using a non-diathermy method performed under local anesthesia. Three cases of excessive post-operation bleeding out of 115 operations (2.61%) occurred.We conclude that an abdominal adipose tissue surgical biopsy using a non-diathermy method can be safely applied to healthy men.
FAQs
The biological material chosen determines which disease-related features an assay can measure. Circulating tumor DNA can provide genetic or epigenetic information, circulating tumor cells offer cellular material for analysis, and extracellular vesicles can carry genetic or protein characteristics. Liquid biopsy development therefore compares these signal types according to the information needed for detection, profiling, treatment selection, or monitoring.
Disease-related signals may be difficult to distinguish from background material in a body-fluid sample. Development efforts consequently focus on improving analytical sensitivity while determining whether detected genetic, epigenetic, or protein changes are clinically meaningful. This balance matters because a technically detectable signal must also support dependable interpretation for medical decisions or longitudinal disease assessment.
Next-generation sequencing and digital PCR provide analytical approaches for examining isolated liquid-biopsy material. Sequencing can support characterization of genetic or epigenetic features, while digital PCR is another method for analyzing selected signals with high analytical sensitivity. Their inclusion in assay development reflects the need to measure disease-associated changes accurately enough for profiling, treatment selection, or monitoring.
A development workflow begins by selecting a measurable signal, such as circulating tumor DNA, circulating tumor cells, or extracellular vesicles. The signal is then analyzed for genetic, epigenetic, or protein characteristics using an appropriate method, followed by validation of analytical sensitivity and meaningful signal discrimination. The final stage concerns establishing reliable standards for clinical integration.
Validated liquid-biopsy assays can contribute to several cancer-care decisions. Their results may assist with cancer detection, molecular profiling, treatment selection, and monitoring response over time. Because the assays examine disease-related signals in body fluids, repeated testing can also support assessment of emerging resistance, provided the method has demonstrated sufficient reliability for the intended clinical use.
Serial analysis of disease-related signals can provide information about how a cancer changes during treatment. Molecular findings may be compared over time to support monitoring of response or to identify evidence of emerging resistance. This application makes assay consistency especially important, since changing results must reflect clinically relevant disease biology rather than variation caused by inadequate sensitivity or unreliable standards.
Validation standards help determine whether an assay consistently detects and interprets the intended disease-related signal. They address analytical sensitivity, separation of meaningful findings from background material, and the reliability needed for clinical integration. In medicine, this validation connects laboratory measurements with practical uses such as detection, molecular profiling, treatment selection, and ongoing monitoring.